- Exchange: Tokyo
- Sector: Consumer, Non-cyclical
- Industry: Pharmaceuticals
- Sub-Industry: Medical-Drugs
More on 4523
News for Eisai Co Ltd (4523)
-
COMPANY NEWS
-
PRESS RELEASES
-
INDUSTRY NEWS
- Arena’s FDA-Approved Weight Loss Pill Clears DEA Hurdle
- Arena Withdrawing Obesity Drug Regulatory Application in Europe
- Arena Joins Vivus Finding Obesity Drugs Fizzle on Costs
- Eisai Cuts Full-Year Profit Forecast 20% as Aricept Sales Drop
- Arena Seeks Partners in Europe, China for Obesity Drug
- Eisai’s Breast Cancer Drug Failed to Show Advantage Over Xeloda
- Lundbeck to Begin Late-Stage Trials on Alzheimer’s Drug Mid-2013
- Vivus Jumps on Aetna Qsymia Ruling: San Francisco Mover
- Eisai Epilepsy Medicine Wins U.S. Approval for Seizures
- Lundbeck in Talks With Possible Alzheimer’s Drug Partners
- Eisai’s Epilepsy Drug Helps Obese Patients Reduce Weight
- Obesity Drugs Gain Attention on FDA Backing for Therapies
- FDA Sued by Consumer Group Over Alzheimer Drug Dosage
- Lundbeck in Talks With Possible Alzheimer’s Drug Partners
- New Sleeping Pill Thwarts Brain’s Up-All-Night Neurons
- Eisai Highlights New Research On Melanoma, Breast and Endometrial Cancer at ASCO Annual Meeting Published May 16, 2013
- Ricardo Gonzalez Balboa Appointed as General Manager of Eisai Laboratorios, S. de R.L. de C.V. Published May 16, 2013
- Helsinn Group and Eisai Inc. Announce Top-Line Results for Pivotal Studies of the Investigational Fixed-Dose Combination of Published May 16, 2013
- First-in-class Fycompa® (perampanel) Pooled Pivotal Phase III Data Published in Epilepsia Published May 12, 2013
- Eisai USA Foundation to Donate $1 Million to the Conquer Cancer Foundation of the American Society of Clinical Oncology Published May 09, 2013
- First Clinical Experiences With Fycompa® (perampanel) Show "Clear Therapeutic Benefit" Published May 09, 2013
- Publication in Federal Register Tomorrow Moves BELVIQ® (lorcaserin HCl) Closer To Launch Published May 07, 2013
- Arena Pharmaceuticals Provides Update on Upcoming US Launch of BELVIQ® (lorcaserin HCl) for Chronic Weight Management Published May 07, 2013
- EU Regulatory Authorities Grant Orphan Status to Eisai's Lenvatinib for the Treatment of Radioiodine-Refractory Differentiated Published May 06, 2013
- Eisai Files for Earlier use of Halaven® (Eribulin) for the Treatment of Metastatic Breast Cancer Published May 06, 2013
- Arena Pharmaceuticals Provides Corporate Update and Reports First Quarter 2013 Financial Results Published May 02, 2013
- Cyclacel Reports Updated Phase 2 Survival Data of Sapacitabine for MDS Published Apr 30, 2013
- GE Healthcare and Eisai Inc. to Partner on Alzheimer’s Disease Research Published Apr 24, 2013
- Merck to Buy Back $5 Billion of Its Shares From Goldman Updated 4 hours ago
- Deutsche Bank Seeks to Avoid Law Suits With Board Changes
- Novartis Ramps Up Alzheimer’s Drug Pursuit as Rivals Fail
- Harvard’s Largest Gift Doubles With Second Wyss Donation
- Kasowitz Benson, Eversheds, Latham, Davis:Business of Law
- German Shares Climb 11th Day as Bullard Backs Bond Plan
- Medtronic’s Heart Rhythm Devices Show Signs of Growth
- Sanofi, Roll Global, Heineken, WWE: Intellectual Property
- China Stocks Rise for Fifth Day, Longest Streak in Three Months
- Novartis Sees MorphoSys Muscle-Atrophy Drug as Exciting
- ‘Love Hormone’ Promises Safer Births After Pfizer Flop
- Teva Bets on Reformulating Old Drugs as Investors Say ‘Show Me’
- Actavis to Buy Warner Chilcott in Women’s Health Effort
- Royalty Pharma Raises Elan Bid to $12.50 a Share in Cash
- Vitamins That Cost Pennies a Day Seen Delaying Dementia
Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.
Advertisements
Advertisement
Rate this Page